Health
Childhood Obesity… A Growing Health Challenge in Modern Societies
By Dr. Najeeb Salah Abdulrahman – Gastroenterology Specialist
Swapna Mary John – Clinical Dietitian, International Modern Hospital Dubai
Modern societies, particularly in the Gulf region, are witnessing a significant rise in childhood obesity rates, making it one of the most pressing health challenges threatening future generations. Obesity is no longer viewed as a simple increase in body weight that can be overlooked; it is now recognized as a complex medical condition influenced by biological, behavioral, and environmental factors, with long-term physical and psychological consequences.
From a medical perspective, childhood obesity is defined as an excessive accumulation of body fat that negatively affects health. It is typically assessed using the Body Mass Index (BMI) in relation to a child’s age and gender. A child is considered obese when their BMI exceeds the 95th percentile for their age and sex. However, numbers alone do not reflect the full extent of the problem, as obesity during childhood often marks the beginning of a path that can lead to chronic diseases at an early age.
According to Dr. Najeeb Salah Abdulrahman, Gastroenterology Specialist, understanding obesity begins within the body itself, particularly in the digestive system, which plays a central role in regulating appetite and metabolism. The digestive system is not merely responsible for processing food; it is a highly integrated system that controls hunger and satiety signals through hormones such as ghrelin and leptin. Imbalances in these hormones can increase appetite or reduce feelings of fullness.
He also explains that changes in the balance of beneficial bacteria within the gut, known as the microbiome, have been linked in recent studies to weight gain. Certain types of bacteria may enhance the body’s ability to extract and store energy from food. However, while this association is promising, the relationship remains under investigation and has not yet been definitively proven as a direct cause of obesity.
Genetics also play an important role. Some children are more predisposed to gaining weight due to genetic influences on appetite regulation, energy expenditure, and the body’s response to food. These genetic factors often interact with lifestyle habits, increasing the likelihood of obesity development.
Another significant factor is insulin resistance, one of the key mechanisms associated with obesity. In this condition, the body becomes less responsive to insulin, leading to increased fat storage and a higher risk of developing type 2 diabetes at a young age.
Swapna Mary John, Clinical Dietitian, emphasizes that lifestyle changes are among the most influential contributors to the growing prevalence of obesity among children. Fast food and processed meals have become a common part of daily life, often containing high levels of saturated fats and sugars while providing limited nutritional value.
She notes that the issue is not only about what children eat but also how they eat. Common behaviors such as eating in front of screens, consuming food out of boredom rather than hunger, and relying heavily on sugary beverages contribute significantly to excess calorie intake.
The environment surrounding children also plays a major role. Technological advancements, despite their many benefits, have significantly reduced physical activity levels. Many children now spend extended periods using electronic devices, reducing daily movement and lowering calorie expenditure.
Lack of sleep is another important factor associated with weight gain. Insufficient sleep affects hormones that regulate appetite, making children more likely to crave foods rich in sugar and fat.
The consequences of childhood obesity extend far beyond physical appearance. Obese children are at greater risk of developing conditions that were once considered adult diseases, including type 2 diabetes, high blood pressure, and abnormal blood lipid levels.
Dr. Najeeb points out that obesity directly affects the digestive system, increasing the likelihood of developing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition that often progresses silently without obvious symptoms but can lead to serious complications if left untreated.
Obesity may also contribute to gastrointestinal disorders such as chronic constipation and increase the risk of gastroesophageal reflux disease (GERD), which can cause persistent heartburn and discomfort.
On the psychological side, Swapna Mary John explains that children struggling with obesity frequently face emotional and social challenges, including bullying, social isolation, and low self-esteem. In some cases, these experiences may contribute to anxiety and depression.
These psychological effects can lead children to use food as a coping mechanism, creating a vicious cycle that further complicates weight management and often requires professional intervention.
Addressing childhood obesity requires a comprehensive approach involving the child, the family, and healthcare professionals. Quick fixes and restrictive diets are rarely effective. Instead, the focus should be on gradual and sustainable lifestyle changes.
Swapna Mary John stresses the importance of developing a healthy relationship between children and food. Children should learn how to make nutritious food choices without feeling deprived. She recommends gradually introducing fruits and vegetables while reducing reliance on sugary snacks and processed foods.
Dr. Najeeb highlights the importance of medical follow-up, particularly when obesity is accompanied by health complications. In such cases, laboratory investigations may be needed to assess liver function, blood sugar levels, and cholesterol profiles.
The family’s role is equally important. Parents serve as the primary role models for children’s eating and lifestyle habits. When children observe healthy behaviors at home, they are more likely to adopt them.
For this reason, healthy lifestyle changes should involve the entire family. Eating nutritious meals together, encouraging outdoor activities, walking, and participating in sports can be far more effective than imposing restrictions solely on the child.
Prevention remains the best strategy and should begin early in life. Establishing healthy eating habits during childhood and encouraging regular physical activity can significantly reduce the risk of obesity.
Schools also have a crucial role in promoting health awareness by offering healthier food options, encouraging sports participation, and implementing educational programs focused on proper nutrition.
Given today’s challenges, collaboration among healthcare providers, educational institutions, and media organizations is essential to raise awareness about the risks of childhood obesity and the importance of prevention.
Childhood obesity is not an inevitable outcome. It is the result of multiple factors that can be managed through awareness, education, and commitment. Every small step toward a healthier lifestyle can make a meaningful difference in a child’s future.
Building a healthier generation begins with simple daily choices, but their impact can last a lifetime, creating a more informed and healthier society capable of facing future health challenges.
Health
Novartis: Rare muscle disease drug shows early promise
Novartis (NOVN.S), opens new tab said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of Avidity, showed promise in an early-to-mid-stage study in patients with a type of genetic muscle disorder characterized by slowly progressive muscle weakness.
- The Swiss drugmaker said the drug, known as del-brax, lowered two blood markers linked to the disease and showed reduced signs of muscle damage in patients with facioscapulohumeral muscular dystrophy.
- Novartis said the drug shows potential to become the first disease-modifying treatment for FSHD, which can cause weakness in the face, shoulders, arms and other muscles.
- The company estimates it affects about 45,000 to 87,000 people in the U.S. and EU.
- The drug’s safety profile was consistent with previous results, the company said.
- Novartis plans to discuss the data with health regulators around the world, while a late-stage study of the drug is currently enrolling patients.
Health
Obesity drug shows promise in reducing belly and liver fat
Boehringer Ingelheim said on Sunday its experimental obesity drug cut visceral and liver fat while minimizing loss of lean mass in a late-stage study, data showed, bolstering its case for benefits beyond weight loss as competition in obesity drugs intensifies.
The drug, survodutide, was licensed from Denmark’s Zealand Pharma (ZELA.CO), opens new tab. An injectable that mimics the proteins GLP-1 and glucagon to create a feeling of fullness, its weight-loss trial results were announced in April, showing patients lost an average of 16.6% over 76 weeks.
Analysis of a group of patients who had MRI measurements at the start and end of a 76-week trial showed that survodutide reduced harmful abdominal fat by up to 34% and liver fat by up to 63.1% from the baseline, Boehringer said.
Analysts have said the weight-loss numbers were broadly comparable to existing GLP-1 injections from Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab and below newer rivals in development, and that the company needed to differentiate the drug’s benefits.
Lean mass accounted for no more than 10.8% of the change in body composition at the highest dose of 6 milligrams, suggesting the weight loss was driven mainly by fat reduction.
The drug’s effect on liver-fat reduction and preservation of lean mass are central to whether it will be able to stand out commercially, alongside tolerability and how long patients stay on the drug. Detailed data from the study could help Boehringer make a stronger case that survodutide should be judged not only by pounds lost but by where weight is lost.
“We believe survodutide will become an important new option at the intersection of obesity and liver disease, two conditions that are deeply connected but rarely addressed together,” said Boehringer executive Shashank Deshpande, who leads the company’s human medicines business.
Boehringer acquired the rights in 2011 to solely develop and commercialise survodutide from Zealand, which is entitled to royalty payments on global revenue.
PATIENTS WITH LIVER DISEASE BENEFIT
In a separate late-stage study of overweight or obese patients with a fatty liver disease called MASLD, survodutide met both its main goals.
After 48 weeks, up to 84.2% of patients on the drug showed a liver fat reduction of at least 30%, compared with 24.3% for those on placebo. Patients on survodutide also lost up to 12.2% of their body weight, versus 1% for placebo.
In 61% of the patients the drug helped achieve liver fat normalization, or a liver fat content below 5%, compared with 5.7% on placebo.
U.S. biotech Altimmune (ALT.O), opens new tab is also developing a drug that targets both the appetite-suppressing gut hormone, GLP-1, and glucagon.
Survodutide is also being tested in other late-stage studies, including for patients with fatty liver disease and fibrosis.
REUTERS
Health
Millions with breast cancer could safely skip chemotherapy
Millions of people with breast cancer could safely avoid chemotherapy as scientists have developed a DNA test that can distinguish between patients who are likely to benefit from the treatment and those who are not, according to trial results.
The international study found that more than two-thirds of its participants could be spared the side of effects of chemotherapy and treated with hormone therapy alone.
Chemotherapy can cause fatigue, nausea, hair loss, a weakened immune system and fertility issues.
The study, led by University College London (UCL), involved more than 4,000 newly diagnosed patients over the age of 40 in the UK, Norway, Sweden, Australia, New Zealand and Thailand.
Scientists used a gene test called Prosigna to measure the activity of 50 genes involved in breast cancer growth and calculate a patient’s risk of the disease returning.
Those who received a low score – two-thirds of the group – were not treated through chemotherapy. The five-year survival rate of their group was 93.7%, compared with a 94.9% rate among patients who received chemotherapy as part of their care.
The primary treatment for breast cancer is usually surgery to remove tumours. Chemotherapy is often recommended afterwards to diminish the risk of return.
It is also regularly offered to people with early-stage breast cancer that has spread to the nearby lymph nodes.
Clinicians are concerned the treatment provides little benefit to those with the most common type of breast cancer, UCL said.
The university said more than 5,000 NHS patients a year could avoid chemotherapy as a result of the trial.
Karen Bonham, from Cardiff, took part in the trial and said the results are an “immense relief” and feel “like Christmas”.
The 64-year-old avoided chemotherapy thanks to the Prosigna test and has instead received radiotherapy and hormone therapy over eight years.
“Cancer diagnosis and treatment can be shocking,” she said.
“It certainly propels you into a world of uncertainty. Life priorities realign – you simply want to survive.”
The findings of the study will be presented at the world’s largest cancer conference, the American Society of Clinical Oncology’s annual meeting, in Chicago, United States, on Saturday.
Professor David Miles, a leading cancer specialist, described the findings as “practice-changing”.
“We can now confidently predict many patients will get no benefit at all, and therefore there’s no need for them to have the chemotherapy,” he told BBC’s Newshour.
He added that the test would allow doctors to “confidently define a large population of women who simply aren’t going to benefit and don’t need to go through all that unpleasantness for no benefit at all.”
“We used to give chemotherapy to 100 women to benefit 10, knowing that 90 didn’t need it,” he said.
Tanya Hutson, who was diagnosed with breast cancer in 2022 and had chemotherapy as part of her treatment, called the new DNA test “absolutely amazing”.
“It just proves what happens when money is put into research,” she said, adding that chemotherapy had been “brutal”.
“For all these people out there who don’t need it but are still getting it – it’s an absolute game changer.”
It is not known whether the findings apply to people under the age of 40, with a result still several years away, according to UCL.
BBC
-
Discover5 months agoIs February 2026 really a once-in -283-years MiracleIn?
-
Entertainment4 months agoNetflix to Livestream BTS Comeback Concert
-
Football6 months agoAlgeria, Burkina Faso, Côte d’Ivoire win AFCON 2025 openers
-
Health5 months agoNMC Royal Hospital, Khalifa City, performs rare wrist salvage, restoring function for young patient
-
Health6 months agoBascom Palmer Eye Institute Abu Dhabi and Emirates Society of Ophthalmology Sign Strategic Partnership Agreement
-
Health7 months agoEmirates Society of Colorectal Surgery Concludes the 3rd International Congress Under the Leadership of Dr. Sara Al Bastaki
-
Lifestyle7 months agoSaudi Arabia Lifestyle Trends 2025: What You Need to Know About Fitness, Wellness, Healthy Eating & Self-Care Growth
-
Health7 months agoBorn Too Soon: Understanding Premature Birth and the Power of Modern NICU Care
